Fortrea Holdings Earnings Call Transcripts
Fiscal Year 2026
-
The meeting established a quorum and proceeded with three proposals: election of directors, ratification of the auditor, and advisory approval of executive compensation. All proposals received the requisite votes for approval, with final results to be filed in a Form 8-K.
-
Demand and bookings are improving across pharma and biotech, with clinical pharmacology rebounding fastest. Revenue is stabilizing, cost savings are on track, and sales strategies are more targeted. AI is a key topic but will take years to impact workflows, while technology upgrades and client diversification support future growth.
-
Q1 2026 saw strong commercial momentum, margin expansion, and improved operational efficiency, with a book-to-bill of 1.15x and significant gains in biotech and China. Revenue declined 2.3% year-over-year, but adjusted EBITDA and net income improved, supporting reaffirmed full-year guidance.
-
Emerging from its spin-off, the company is leveraging decades of expertise and technology to modernize clinical trial delivery, focusing on execution, margin expansion, and sustainable growth. Optimism in pharma R&D investment and disciplined capital allocation support its multi-year strategy.
Fiscal Year 2025
-
Revenue and Adjusted EBITDA met guidance for 2025, with strong cash flow and cost savings. 2026 guidance anticipates stable revenue, margin improvement, and continued cost optimization, supported by improved biotech funding and operational efficiency.
-
Leadership transition is progressing well, with strategic changes underway and a focus on growth through new customer acquisition and operational improvements. Market sentiment is improving, technology innovation is driving efficiency, and cost discipline is supporting margin expansion and leverage reduction.
-
Sequential improvement in bookings and strong pipeline momentum are supported by operational changes, cost actions, and a bespoke client model. Financial guidance is raised, debt reduction continues, and margin expansion is targeted through efficiency and disciplined pricing.
-
Q3 2025 saw revenue of $701.3M and adjusted EBITDA of $50.7M, with improved win rates and a book-to-bill ratio of 1.13. Raised full-year revenue guidance and continued cost optimization, while maintaining strong liquidity and focusing on margin improvement.
-
Q2 2025 revenue grew 7.2% year-over-year to $710.3 million, with adjusted EBITDA of $54.9 million and a raised full-year revenue outlook. A $309.1 million goodwill impairment drove a net loss, but operational improvements, cost savings, and strong clinical pharmacology performance support a positive outlook.
-
Leadership transition is progressing with a new CEO expected by summer's end, while operational priorities focus on cost management, IT rationalization, and maintaining strong client relationships. Large pharma demand is steady, biotech is cautious but stable, and FSP partnerships are a renewed focus.
-
Q1 2025 revenues and adjusted EBITDA met expectations, with guidance reaffirmed despite a 1.6% revenue decline and a significant goodwill impairment. Transformation efforts are underway to improve margins and reduce SG&A, while the CEO transition is in progress.
Fiscal Year 2024
-
Q4 saw strong bookings and a $7.7B backlog, but 2025 guidance is lower due to slow-burning, less profitable pre-spin projects. Transformation programs target $40–$50M in SG&A savings, with growth and margin improvement expected in 2026 as new business ramps up.
-
Q3 2024 saw solid execution with a 1.23x book-to-bill, $674.9M revenue, and $64.2M adjusted EBITDA. Backlog grew to $7.6B, and margin expansion efforts continued amid ongoing TSA exit and IT transitions. Guidance for 2024 revenue was slightly lowered, but EBITDA guidance held steady.
-
Strong bookings, balanced customer mix, and operational transformation have positioned the company for improved predictability and margin expansion. Technology and data partnerships, along with disciplined financial management and a focus on culture, support growth targets into 2025.
-
Q2 2024 saw revenue and EBITDA declines year-over-year, but sequential margin improvement and strong cash flow. Book-to-bill was below target due to biotech delays, but a robust pipeline and large pharma wins support improved H2 and 2025 outlooks.
-
Jill McConnell discussed operational progress post-spin, including significant debt reduction, a focus on execution and backlog, and ongoing SG&A and margin improvements. The company remains committed to its guidance and expects revenue growth to accelerate in the second half of 2024.
-
The company is nearing its one-year anniversary post-spin, maintaining a strong book-to-bill ratio and focusing on commercial transformation, data partnerships, and site support. Recent asset sales are reducing debt, while operational and financial initiatives aim to improve margins and project execution.